
Tenax Therapeutics, Inc.: financial statements
Price
$1.25
November 20, 2026Market cap $57M
What Ploutos Investor adds for Tenax Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from FY2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 23% since Nov 5, 2026, when the 10-Q these figures come from was filed ($1.63 then, $1.25 on Nov 20, 2026). The figures date from before that move.10-Q
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
| Line | 2016 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | |
| Cost of revenue | $0 | – | – | |
| Gross profit | $0 | – | – | |
| Operating income | -$53M | -$19M | -$56M | |
| Net income | -$44M | -$18M | -$53M | |
| Earnings per share | -$1.56 | -$1.15 | -$1.34 | |
| Earnings per share, basic | -$1.56 | -$1.15 | -$1.34 |
Financial statements
TENX's revenue, profits and cash flows from FY2011 to FY2015, 5 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
0.0%
The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Other
+1.0 pts
State and local taxes
+0.1 pts
Change in valuation allowance
-16.5 pts
Share-based compensation
-5.6 pts
Effective rate
0.0%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
Effective tax rate by year
The tax rate TENX paid on its profit, from 2018 to 2022, 5 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Tenax Therapeutics's filings show?
These are Tenax Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did TENX have in 2025?
Tenax Therapeutics had revenue of $0 and net income of -$53M in fiscal 2025, a net margin of .
How much debt does TENX have?
On December 31, 2025 Tenax Therapeutics had total assets of $104M, debt of – and shareholders' equity of $97M.
Where are the figures from?
From Tenax Therapeutics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.